Will formal entry into the European Union enable the eight new Central European members to galvanize their biotech sectors? Clare Sansom reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sansom, C. European biotechnology turns east. Nat. Biotechnol. 17, 437–439 (1999).
Dickson, D. et al. What next for science in Central Europe. Nature 372, 591–592 (1994).
European Commission Directorate-General for Research. Towards a European Research Area Science, Technology, Innovation (European Commission, Brussels, Belgium, 2003).
European Commission. Eurobarometer 2003. 4. Public Opinion in the Candidate Countries (European Commission, Brussels, Belgium, 2004).
Petition for a new and ambitious European science policy (European Life Scientist Organization, posted February 24, 2004). http://ultr23.vub.ac.be/petition/
Vanecek, J. Pharmacy and biotechnology in the Czech Republic. http://www.tc.cz/dokums/biotechnology_in_czech9uk-revision_1100_1.pdf
Ernst and Young. Beyond Borders. The Global Biotechnology Report, 2002 (Ernst and Young, New York, June 2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sansom, C. EU expansion: enlarged horizons or false dawn?. Nat Biotechnol 22, 501–504 (2004). https://doi.org/10.1038/nbt0504-501
Issue Date:
DOI: https://doi.org/10.1038/nbt0504-501
This article is cited by
-
More than the sum of their parts?
EMBO reports (2006)